Indoco Remedies receives EIR for its Goa manufacturing facilities; share price rises 5%
The inspection classification of this site has been determined as VAI (Voluntary Action Indicated) by the USFDA.25-11-2019
25-11-2019
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco receives EIR for its manufacturing facilities in Goa (Plant II & III)25-11-2019
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco receives EIR for its manufacturing facilities in Goa (Plant II & III)25-11-2019
Indoco Remedies Ltd - 532612 - Submission Of Half Yearly Disclosure On RPT
Regulation 23(9) of SEBI (LODR) Regulations, 2015 (Listing Regulations)19-11-2019
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Approval of Glycopyrrolate ANDA filed from Indoco''s Goa Plant II01-11-2019
Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Unaudited Financial Results for the quarter and half year ended 30.09.201931-10-2019
Indoco Remedies posts net profit of Rs 7.81 cr in Q2
Drug firm Indoco Remedies on Wednesday reported a consolidated net profit of Rs 7.81 crore for the quarter ended September 30.The company had posted a30-10-2019
INDOCO REMEDIES LTD. - 532612 - UNAUDITED FINANCIAL RESULTS
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.201930-10-2019
INDOCO REMEDIES LTD. - 532612 - Regulation 40(10)
Certificate under Clause 40 of SEBI (LODR) Reg, 2015 for half year ended 30.09.201918-10-2019
INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco''s Clinical Research Organisation receives zero 483s from USFDA18-10-2019